ARGX vs VRTX
argenx SE and Vertex Pharmaceuticals, both Healthcare
Vertex Pharmaceuticals is the larger company at $115B against $55B. On trailing earnings VRTX is the cheaper of the two at a P/E of 31.9 against 53.5, a gap that is only a bargain if the two are growing at similar rates. Over the past year ARGX returned +56% against +42% for VRTX. Ryufin's sector-relative Smart Score puts VRTX ahead, 8/10 against 7/10.
| Figure | ARGX | VRTX |
|---|---|---|
| Last close | $1047 | $547 |
| Market cap | $55B | $115B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 53.5 | 31.9 |
| 1-year return | +56% | +42% |
| 5-year return | +239% | +171% |
| Ryufin Smart Scoresector-relative, 1–10 | 7/10 | 8/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
argenx SE
Revenue of $2.5B in H2 2025, net income $877M.
Vertex Pharmaceuticals
Revenue of $3.3B in Q2 2026, net income $1.1B. Its largest reported line is TRIKAFTAKAFTRIO, 79% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.